Fenwick represented ESCAPE Bio, a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, in its $73 million crossover financing. The financing was led by Wellington Management Company LLP, with participation from Avidity Partners, CAM Capital, New Leaf Ventures, Rock Springs Capital, Surveyor Capital (a Citadel company) and Sphera Funds Management.
The funding will be used to advance Escape Bio’s pipeline of precision neurology medicines for genetic neurodegeneration and allow the company to accelerate two programs into patients who lack disease modifying treatments. More information can be obtained from Escape Bio’s announcement.
The Fenwick transaction team was led by corporate partner Effie Toshav and associates Elliot Ginsburg and Ethan Mackay.